194 related articles for article (PubMed ID: 2459370)
1. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
2. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
3. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
4. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
6. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh SL; Preston KL; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
9. Assessment of buprenorphine in a drug discrimination procedure in humans.
Bigelow GE; Preston KL
NIDA Res Monogr; 1992; 121():28-37. PubMed ID: 1406908
[TBL] [Abstract][Full Text] [Related]
10. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
Jones HE; Bigelow GE; Preston KL
J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
12. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.
Schuh KJ; Walsh SL; Stitzer ML
Psychopharmacology (Berl); 1999 Jul; 145(2):162-74. PubMed ID: 10463317
[TBL] [Abstract][Full Text] [Related]
13. Drug discrimination in human post-addicts: agonist/antagonist opioids.
Preston K; Bigelow G; Bickel W; Liebson I
NIDA Res Monogr; 1988; 81():209-15. PubMed ID: 2457160
[No Abstract] [Full Text] [Related]
14. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
[TBL] [Abstract][Full Text] [Related]
15. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
Preston KL; Bigelow GE; Bickel W; Liebson IA
J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
[TBL] [Abstract][Full Text] [Related]
16. Drug discrimination in human postaddicts: agonist-antagonist opioids.
Preston KL; Bigelow GE; Bickel WK; Liebson IA
J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
[TBL] [Abstract][Full Text] [Related]
17. The effects of buprenorphine in methadone-dependent volunteers.
Strain EC; Bigelow GE; Preston KL; Liebson I
NIDA Res Monogr; 1990; 105():584. PubMed ID: 1715035
[No Abstract] [Full Text] [Related]
18. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
[TBL] [Abstract][Full Text] [Related]
19. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids.
Mutschler NH; Stephen BJ; Teoh SK; Mendelson JH; Mello NK
Nicotine Tob Res; 2002 May; 4(2):223-8. PubMed ID: 12028854
[TBL] [Abstract][Full Text] [Related]
20. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
Preston KL; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
